Patents Assigned to North Carolina Central University
-
Publication number: 20210177974Abstract: A delivery system using materials that form a liquogel or nanocarrier are described. The delivery system comprises hyperbranched polyglycerols (HPGs). The delivery system can include a drug or therapeutic agent and this system can be used to administer the drug or therapeutic agent locally. The delivery system provides for controlled release of the drug or therapeutic agent.Type: ApplicationFiled: October 16, 2020Publication date: June 17, 2021Applicant: NORTH CAROLINA CENTRAL UNIVERSITYInventors: Darlene K. Taylor, Melony A. Ochieng
-
Publication number: 20210148909Abstract: An assay and a method for detecting how much active PCSK9 is available in a sample to bind to the LDL receptor. Active PCSK9 is PCSK9 that is not bound to a LDL receptor and is available to bind to a LDL receptor. An aspect of the assay and method involves the use of LDL receptor and a PCSK9 specific antibody to identify, detect or quantify the PCSK9/LDL receptor complexes.Type: ApplicationFiled: May 31, 2017Publication date: May 20, 2021Applicant: NORTH CAROLINA CENTRAL UNIVERSITYInventor: Dayami LOPEZ
-
Publication number: 20210087163Abstract: This invention relates generally to compounds that are glucuronidase inhibitors. The glucuronidase inhibitors include phenoxy thiophene sulfonamides, and other compounds such as pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls. These compounds include nialamide, isocarboxazid, phenelzine, amoxapine, loxapine and mefloquine. Also compositions including one or more of such compounds for use in inhibiting glucuronidase and methods of using one or more of such compounds for selective inhibition of bacterial ?-glucoronidase. These compounds may be used as a co-drug in combination with the anticancer drug CPT-11. Also a method for screening compounds to determine their usefulness in reducing diarrhea associated with irinotecan chemotherapy.Type: ApplicationFiled: December 1, 2020Publication date: March 25, 2021Applicants: NORTH CAROLINA CENTRAL UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: ALFRED L. WILLIAMS, JOHN E. SCOTT, LI-AN YEH, MATTHEW R. REDINBO
-
Patent number: 10342766Abstract: Derivatives of 6-shogaol are described herein. Also described herein are methods of preparing the derivatives, as well as methods of using the derivatives to activate Nrf2 and to treat diseases associated with inflammation and/or oxidative stress.Type: GrantFiled: March 23, 2018Date of Patent: July 9, 2019Assignees: North Carolina Agricultural and Technical State University, North Carolina Central UniversityInventors: Shengmin Sang, Yingdong Zhu, TinChung Leung
-
Patent number: 10344107Abstract: A styrene based water soluble polymer containing pendant sulfonated calix[4]arene groups has been synthesized by using free radical polymerization combined with post-polymerization sulfonation chemistry. The monomer 25-(4-vinylbenzyl)-26, 27, 28-hydroxy-calix[4]arene was prepared in 3 steps: (1) reduction of 4-vinyl benzoic acid to the respective alcohol (2) formation of the bromide by the Appel reaction and (3) synthesis of the respective ether by Williamson O-alkylation reaction with calix[4]arene. Polymerization was accomplished by azobisisobutyronitrile (AIBN) initiated free radical polymerization technique. Electro-responsive properties of the sulfonated polymer were studied wherein a response to electrochemical stimulus is observed when guest molecules of methyl viologen are incorporated with polymerized 25-(4-vinylbenzyl)-26, 27, 28-hydroxy-calix[4]arene.Type: GrantFiled: November 14, 2014Date of Patent: July 9, 2019Assignee: NORTH CAROLINA CENTRAL UNIVERSITYInventors: Darlene K. Taylor, Uddhav Balami
-
Publication number: 20180280320Abstract: Derivatives of 6-shogaol are described herein. Also described herein are methods of preparing the derivatives, as well as methods of using the derivatives to activate Nrf2 and to treat diseases associated with inflammation and/or oxidative stress.Type: ApplicationFiled: March 23, 2018Publication date: October 4, 2018Applicants: North Carolina Agricultural and Technical State University, North Carolina Central UniversityInventors: Shengmin Sang, Yingdong Zhu, TinChung Leung
-
Patent number: 10005720Abstract: The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.Type: GrantFiled: April 4, 2014Date of Patent: June 26, 2018Assignees: North Carolina Central University, The University of North Carolina at Chapel HillInventors: Jonathan Z. Sexton, Jay E. Brenman, David L. Musso
-
Patent number: 9879324Abstract: Described are methods of determining if a subject has a genetic predisposition to developing prostate cancer (PCa) or aggressive PCa, or to developing breast cancer (BrCa).Type: GrantFiled: March 30, 2012Date of Patent: January 30, 2018Assignees: University of Louisville Research Fondation, Inc., North Carolina Central UniversityInventors: La Creis Renee Kidd, Kevin Sean Kimbro
-
Patent number: 9863002Abstract: Described are methods of determining if a subject has a genetic predisposition to developing prostate cancer (PCa), e.g., an American or Caribbean subject of African descent and of reducing their risk.Type: GrantFiled: May 31, 2013Date of Patent: January 9, 2018Assignees: North Carolina Central University, University of Louisville Research FoundationInventors: La Creis Renee Kidd, Kevin Sean Kimbro
-
Publication number: 20170333356Abstract: The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.Type: ApplicationFiled: August 1, 2017Publication date: November 23, 2017Applicants: BioSpecifics Technologies Corp., Duke University, North Carolina Central UniversityInventors: Phyllis Carolyn Leppert, Thomas L. Wegman, Darlene K. Taylor
-
Patent number: 9744138Abstract: The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.Type: GrantFiled: March 14, 2014Date of Patent: August 29, 2017Assignees: BioSpecifics Technologies Corp., Duke University, North Carolina Central UniversityInventors: Phyllis Carolyn Leppert, Thomas L. Wegman, Darlene K. Taylor
-
Patent number: 9617239Abstract: This invention relates generally to compounds that are glucuronidase inhibitors. Glucuronidase inhibitors described include phenoxy thiophene sulfonamides. Other compounds, for instance pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls, are also contemplated. Also contemplated are compositions including one or more of such compounds for use inhibiting glucuronidase and methods of using one or more of such compounds as a co-drug to be used in combination with the anticancer drug CPT-11.Type: GrantFiled: March 10, 2011Date of Patent: April 11, 2017Assignees: North Carolina Central University, The University of North Carolina at Chapel HillInventors: Alfred L. Williams, John Scott, Li-An Yeh, Matthew Robert Redinbo
-
Publication number: 20160289350Abstract: A styrene based water soluble polymer containing pendant sulfonated calix[4]arene groups has been synthesized by using free radical polymerization combined with post-polymerization sulfonation chemistry. The monomer 25-(4-vinylbenzyl)-26,27,28-hydroxy-calix[4]arene was prepared in 3 steps: (1) reduction of 4-vinyl benzoic acid to the respective alcohol (2) formation of the bromide by the Appel reaction and (3) synthesis of the respective ether by Williamson O-alkylation reaction with calix[4]arene. Polymerization was accomplished by azobisisobutyronitrile (AIBN) initiated free radical polymerization technique. Electro-responsive properties of the sulfonated polymer were studied wherein a response to electrochemical stimulus is observed when guest molecules of methyl viologen are incorporated with polymerized 25-(4-vinylbenzyl)-26,27,28-hydroxy-calix[4]arene.Type: ApplicationFiled: November 14, 2014Publication date: October 6, 2016Applicant: NORTH CAROLINA CENTRAL UNIVERSITYInventors: Darlene K. TAYLOR, Uddhav BALAMI
-
Publication number: 20160237058Abstract: This invention relates generally to compounds that are glucuronidase inhibitors. The glucuronidase inhibitors include phenoxy thiophene sulfonamides, and other compounds such as pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls. These compounds include nialamide, isocarboxazid, phenelzine, amoxapine, loxapine and mefloquine. Also compositions including one or more of such compounds for use in inhibiting glucuronidase and methods of using one or more of such compounds for selective inhibition of bacterial ?-glucoronidase. These compounds may be used as a co-drug in combination with the anticancer drug CPT-11. Also a method for screening compounds to determine their usefulness in reducing diarrhea associated with irinotecan chemotherapy.Type: ApplicationFiled: March 3, 2016Publication date: August 18, 2016Applicants: NORTH CAROLINA CENTRAL UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: ALFRED L. WILLIAMS, JOHN E. SCOTT, LI-AN YEH, MATTHEW R. REDINBO
-
Publication number: 20150119325Abstract: The present invention provides methods for the high-level production of recombinant human erythropoietin (rhuEPO) derivative, asialoerythropoietin (asialo-rhuEPO), in plants. The methods for producing asialo-rhuEPO comprise making a plant or at least one plant cell that comprises a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding a human erythropoieting fusion protein and a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding N-glycosylation modification enzyme, particularly a mammalian ?1,4-galactosyltransferase. The present invention further provides plants, plant cells, and seeds that have been genetically modified to produce high levels of asialo-rhuEPO. Additionally, provided are methods for purifying asialo-rhuEPO from plant tissues.Type: ApplicationFiled: March 14, 2013Publication date: April 30, 2015Applicant: NORTH CAROLINA CENTRAL UNIVERSITYInventors: Jiahua Xie, Farooqahmed S. Kittur, Chiu-Yueh Hung
-
Publication number: 20140221226Abstract: Described are methods of determining if a subject has a genetic predisposition to developing prostate cancer (PCa) or aggressive PCa, or to developing breast cancer (BrCa).Type: ApplicationFiled: March 30, 2012Publication date: August 7, 2014Applicants: NORTH CAROLINA CENTRAL UNIVERSITY, UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: La Creis Renee Kidd, Kevin Sean Kimbro
-
Publication number: 20130345235Abstract: This invention relates generally to compounds that are glucuronidase inhibitors. Glucuronidase inhibitors described include phenoxy thiophene sulfonamides. Other compounds, for instance pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls, are also contemplated. Also contemplated are compositions including one or more of such compounds for use inhibiting glucuronidase and methods of using one or more of such compounds as a co-drug to be used in combination with the anticancer drug CPT-11.Type: ApplicationFiled: March 10, 2011Publication date: December 26, 2013Applicants: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, NORTH CAROLINA CENTRAL UNIVERSITYInventors: Alfred L. Williams, John Scott, Li-An Yeh, Matthew Robert Redinbo
-
Patent number: 8557808Abstract: Compounds, compositions and methods are provided that comprise selective ?-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial ?-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial ?-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds.Type: GrantFiled: December 9, 2010Date of Patent: October 15, 2013Assignees: North Carolina Central University, The University of North Carolina at Chapel Hill, Albert Einstein College of Medicine of Yeshiva UniversityInventors: Matthew R. Redinbo, Sridhar Mani, Alfred Williams, John Scott, Li-An Yeh, Bret David Wallace, Kimberly Terry Lane
-
Publication number: 20130217789Abstract: A delivery system using materials that form a liquogel or nanocarrier are described. The delivery system comprises hyperbranched polyglycerols (HPGs). The delivery system can include a drug or therapeutic agent and this system can be used to administer the drug or therapeutic agent locally. The delivery system provides for controlled release of the drug or therapeutic agent.Type: ApplicationFiled: September 2, 2011Publication date: August 22, 2013Applicant: NORTH CAROLINA CENTRAL UNIVERSITYInventors: Darlene K. Taylor, Melony A. Ochieng
-
Publication number: 20130195815Abstract: A method for labeling insulin-secreting pancreatic ?-cells in human islets by using a genetically-encoded preproinsulin fluorescent protein reporter which targets an insulin fusion protein to correct insulin vesicles. The reporter system comprising an insulin and fluorescent protein construct provides real time tracking of secretory granules in live cells and allows for the accurate measuring of the level of secretion. The labeled cells are sorted by fluorescence-activated cell sorting to obtain purified insulin-secreting pancreatic ?-cell pools from human islets. The ?-cell pools are suitable for transplantation into the pancreas of diabetics in order to treat diabetes.Type: ApplicationFiled: October 12, 2012Publication date: August 1, 2013Applicant: NORTH CAROLINA CENTRAL UNIVERSITYInventor: NORTH CAROLINA CENTRAL UNIVERSITY